
Opinion|Videos|March 5, 2024
Initial Impression of Case
Author(s)Robert J. Motzer, MD
Dr. Motzer provides his perspective on the notable aspects of this nccRCC case and how it compares to typical cases.
Advertisement
Episodes in this series

Now Playing
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
3
Alpelisib/Fulvestrant Improves PFS in Post-CDK4/6 HR+/HER2- Breast Cancer
4
Real-World Pola-R-CHP vs R-CHOP Effectiveness in Older DLBCL Patients
5









































